ArticleClinical rheumatology2026
Usefulness of salivary gland ultrasonography in Sjögren's syndrome: The Tunisian Experience.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnostic performance of salivary gland ultrasonography using the OMERACT scoring system in Sjögren disease: A cross-sectional diagnostic accuracy study.Therapeutic advances in musculoskeletal disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary Sjögren's syndrome (pSS) is a systemic autoimmune epithelitis characterized by lymphocytic infiltration of exocrine glands, leading to sicca symptoms. The 2016 ACR/EULAR classification criteria emphasize objective diagnostic markers, notably minor salivary gland biopsy and anti-SSA/Ro antibodies. However, minor salivary gland biopsy is invasive and not always feasible. Salivary gland ultrasonography (SGUS), particularly with the OMERACT scoring system, has emerged as a non-invasive tool to evaluate glandular abnormalities. This study aimed to assess the diagnostic performance of SGUS using the OMERACT score in patients with suspected pSS.
methodsWe conducted a cross-sectional study from June 2022 to January 2024, including 94 patients referred for sicca symptoms. All patients underwent clinical evaluation, serological testing ophthalmologic assessment, minor salivary gland biopsy, and SGUS. SGUS was performed using a standardized protocol and scored according to the OMERACT semi-quantitative system (grades 0-3 per gland).
resultsAmong the 94 patients, 50 fulfilled the criteria for pSS. The mean age was 57 ± 12.5 years, and 83% were women. SGUS abnormalities particularly heterogeneous echotexture and hypoechogenicity were significantly more prevalent in the pSS group. An OMERACT score > 1 was observed in 44% of pSS patients versus 7% of controls (p < 0.001). ROC analysis revealed an AUC of 0.727 (95% CI: 0.645-0.809). Using an OMERACT score > 1 as the threshold, SGUS had a sensitivity of 40%, specificity of 93%, positive predictive value of 87%, and negative predictive value of 57%.
conclusionSGUS, which uses the OMERACT scoring system, is a specific, noninvasive imaging modality that can aid in the diagnosis of pSS. Although it is not a substitute for histology or serology, SGUS may be a valuable complementary tool, especially when biopsies are unavailable or declined. Key Points • SGUS using the OMERACT score shows high specificity (93%) for diagnosing primary Sjögren's syndrome. • An OMERACT score >1 strongly supports the diagnosis, though sensitivity remains modest. • SGUS is a valuable complementary, non-invasive alternative when biopsy is not feasible.
Indexed as
Identifiers
41454202What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.